3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Merger Agreement Between Ligand Pharmaceuticals and XOMA Royalty
Reports First Quarter 2026 Financial Results
Termination of TR-Beta Program - Ligand Pharmaceuticals Notifies Viking
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results
Ligand Pharmaceuticals Announces Private Placement Investment in Athira Pharma
Reports Third Quarter 2025 Financial Results and Raises Guidance
News, Material Contracts
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Amended Notice of Proposed Sale of Securities